3 Regional Hospital Network, Molecular Diagnostics Platform and Pathology and Imaging Chain Stocks With a Strong Future Roadmap: Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre
- October 23, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre: ROE of 10.7% to 18.1% and FY22 to FY26 revenue CAGR of 15.1% to 23.8%. Prices as of 22 Oct 2026.
Quick Answer
The three regional hospital and point-of-care test stocks to watch are Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre. Their return on equity ranges from 10.7% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.1% to 23.8%. Vijaya Diagnostic Centre has the highest return on equity at 18.1%, while Krishna Institute of Medical Sciences has the fastest revenue growth at 23.8% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Regional hospital and point-of-care test stocks let investors follow companies that treat patients and detect disease early. Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre cover a regional hospital network, a portable molecular testing platform and a pathology and imaging chain.
This list covers three regional hospital and point-of-care test stocks with complete current figures: Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Regional Hospital and Point-of-care Test Stocks?
Regional hospital and point-of-care test stocks are listed companies that run hospitals, make testing systems or operate diagnostic centres. Their earnings depend on patient volumes, test volumes and the mix of services.
Regional Hospital and Point-of-care Test Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Krishna Institute of Medical Sciences | 668.55 | 28,495 | 146.5 | 59.6 | 10.7 | 1.89 |
| Molbio Diagnostics | 1,322.6 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
| Vijaya Diagnostic Centre | 1,390.8 | 14,066 | 75.0 | 59.6 | 18.1 | 0.44 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing regional hospital and point-of-care test stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Regional Hospital and Point-of-care Test Stocks Have a Strong Roadmap in India?
Regional hospital and point-of-care test stocks have a strong roadmap in India because better access to testing and treatment in smaller cities is lifting demand beyond the large metros.
- Smaller cities. Hospitals and labs reach patients outside the big metros.
- Point-of-care testing. Portable systems bring lab-grade results to remote places.
- Preventive care. More people opt for regular health checks.
Why Krishna Institute of Medical Sciences Features Among These Regional Hospital and Point-of-care Test Stocks
Among the regional hospital and point-of-care test stocks on this list, Krishna Institute of Medical Sciences, known as KIMS Hospitals, runs a network of multi-specialty hospitals in Telangana, Andhra Pradesh and other states, with strengths in cardiac, neuro and transplant care.
In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%.
Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6.
Roadmap: The company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
What to watch: Track bed additions, occupancy and revenue per occupied bed.
Why Molbio Diagnostics Features Among These Regional Hospital and Point-of-care Test Stocks
Among the point-of-care testing company shares on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Why Vijaya Diagnostic Centre Features Among These Regional Hospital and Point-of-care Test Stocks
Among the three companies on this list, Vijaya Diagnostic Centre is a Hyderabad-headquartered diagnostics chain that offers pathology and radiology services through a network of centres, with Hyderabad and Telangana as its home base.
Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%.
In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6.
Roadmap: The plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.
What to watch: Check the revenue contribution from newer regions and the pace at which new centres turn profitable.
Krishna Institute of Medical Sciences vs Molbio Diagnostics vs Vijaya Diagnostic Centre on Key Financials
The table below sets the three regional hospital and point-of-care test stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Krishna Institute of Medical Sciences | 1,671 | 3,931 | 23.8% | 242 | 6.2% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
| Vijaya Diagnostic Centre | 475 | 835 | 15.1% | 173 | 20.7% |
Vijaya Diagnostic Centre posts the highest return on equity in this group at 18.1%. Krishna Institute of Medical Sciences combines the largest FY26 revenue at Rs 3,931 crore with the fastest revenue growth, a 23.8% compound annual rate. A useful habit with regional hospital and point-of-care test stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Regional Hospital and Point-of-care Test Stocks
Every theme carries risks that deserve a check before any decision. For these regional hospital and point-of-care test stocks, the main points are: Long-term point-of-care testing company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Competition and procurement rules can limit pricing.
- Capacity timing. New centres and hospitals take time to ramp up.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter regional hospital and point-of-care test stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Regional Hospital and Point-of-care Test Stocks
Regional hospital and point-of-care test stocks reward investors who follow patient volumes, test volumes and capacity together. Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre each serve a different step in care. Based on the 22 October 2026 close, Krishna Institute of Medical Sciences trades at Rs 668.55, Molbio Diagnostics at Rs 1,322.6 and Vijaya Diagnostic Centre at Rs 1,390.8. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these regional hospital and point-of-care test stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track regional hospital and point-of-care test stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are regional hospital and point-of-care test stocks?
Ans. Regional hospital and point-of-care test stocks are listed companies that run hospitals, make testing systems or operate diagnostic centres. Their earnings depend on patient volumes, test volumes and the mix of services. This list looks at three of them, Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which regional hospital and point-of-care test stocks are covered in this list?
Ans. This list covers Krishna Institute of Medical Sciences, Molbio Diagnostics and Vijaya Diagnostic Centre. Based on the 22 October 2026 close, Krishna Institute of Medical Sciences traded at Rs 668.55, Molbio Diagnostics at Rs 1,322.6 and Vijaya Diagnostic Centre at Rs 1,390.8. Their return on equity ranges from 10.7% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.1% to 23.8%.
Why do regional hospital and point-of-care test stocks have a strong future roadmap in India?
Ans. Regional hospital and point-of-care test stocks have a strong roadmap in India because better access to testing and treatment in smaller cities is lifting demand beyond the large metros. The main drivers are as follows. Smaller cities. Hospitals and labs reach patients outside the big metros. Point-of-care testing. Portable systems bring lab-grade results to remote places. Preventive care. More people opt for regular health checks. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Krishna Institute of Medical Sciences performed financially?
Ans. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
How has Vijaya Diagnostic Centre performed financially?
Ans. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.
What risks should investors check before buying regional hospital and point-of-care test stocks?
Ans. Investors should check a few risks before buying regional hospital and point-of-care test stocks. Pricing pressure. Competition and procurement rules can limit pricing. Capacity timing. New centres and hospitals take time to ramp up. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of regional hospital and point-of-care test stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
